Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention

  Bladder Cancer, January 2023

Free Subscription


Abstracts

Retrieve all available abstracts of the following 256 articles:
HTML format


 

Single Articles

  1. MUKHERJEE N, Ji N, Tan X, Chen CL, et al
    KLRF1, a novel marker of CD56(bright) NK cells, predicts improved survival for patients with locally advanced bladder cancer.
    Cancer Med. 2022 Dec 29. doi: 10.1002/cam4.5579.
    PubMed    
    Abstract available

  2. WANG J, Chen S, Wang H, Cao J, et al
    Integrated molecular analyses of an interferon-gamma based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification.
    Heliyon. 2022;8:e12102.
    PubMed    
    Abstract available

  3. RIPPING TM, Rammant E, Witjes JA, Aaronson NK, et al
    Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer.
    Health Qual Life Outcomes. 2022;20:171.
    PubMed    
    Abstract available

  4. ZHONG W, Li J, Liu L, Hong P, et al
    Comparison of minimally invasive versus open pelvic organ-preserving radical cystectomy in female patients with bladder cancer: a multicenter propensity score matching analysis.
    World J Urol. 2022 Dec 29. doi: 10.1007/s00345-022-04232.
    PubMed    
    Abstract available

  5. ZHU X, Qin R, Qu K, Wang Z, et al
    Atomic Force Microscopy-based assessment of multimechanical cellular properties for classification of graded bladder cancer cells and cancer early diagnosis using machine learning analysis.
    Acta Biomater. 2022 Dec 26:S1742-7061(22)00838.
    PubMed    
    Abstract available

  6. HAO Y, Chen Y, He X, Han R, et al
    RGD peptide modified platinum nanozyme Co-loaded glutathione-responsive prodrug nanoparticles for enhanced chemo-photodynamic bladder cancer therapy.
    Biomaterials. 2022;293:121975.
    PubMed    
    Abstract available

  7. KANG Z, Dou Q, Huang T, Tu M, et al
    An angiogenesis‑related lncRNA signature for the prognostic prediction of patients with bladder cancer and LINC02321 promotes bladder cancer progression via the VEGFA signaling pathway.
    Mol Med Rep. 2023;27:38.
    PubMed    
    Abstract available

  8. ERIKSSON V, Holmkvist O, Huge Y, Johansson M, et al
    A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naive Cystectomy Patients-A Study of a Clinical Multicent
    J Pers Med. 2022;12:1769.
    PubMed    
    Abstract available


  9. Non-Coding RNA NEAT1/miR-214-3p Contribute to Doxorubicin Resistance of Urothelial Bladder Cancer Preliminary Through the Wnt/beta-Catenin pathway [Retraction].
    Cancer Manag Res. 2022;14:3525-3526.
    PubMed    
    Abstract available

  10. TAO ZL, Wu W, Liang LC, Pan JF, et al
    Case report: Complete response of a bladder cancer patient with multiple hepatic and pelvic metastases treated by nab-paclitaxel combined with sintilimab.
    Front Oncol. 2022;12:1020793.
    PubMed    
    Abstract available

  11. AN B, Guo Z, Wang J, Zhang C, et al
    Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma.
    Front Immunol. 2022;13:1080947.
    PubMed    
    Abstract available

  12. LI J, Wang Y, Zhang X, Yang X, et al
    Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5-mediated p53 degradation blockage.
    Clin Transl Med. 2023;13:e1149.
    PubMed    
    Abstract available

  13. ZHANG B, He Y, Zheng D, Shang P, et al
    Clinical efficacy and prognostic analysis of radical cystectomy plus modified ureterosigmoidostomy (Mainz II) in bladder cancer.
    Asian J Surg. 2022 Dec 26:S1015-9584(22)01765.
    PubMed    


  14. YILMAZ H, Cinar NB, Avci IE, Telli E, et al
    The systemic inflammation response index: An independent predictive factor for survival outcomes of bladder cancer stronger than other inflammatory markers.
    Urol Oncol. 2022 Dec 26:S1078-1439(22)00468.
    PubMed    
    Abstract available


  15. Expression of Concern: Downregulated Long Noncoding RNA PART1 Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer.
    Technol Cancer Res Treat. 2022;21:15330338221146361.
    PubMed    


  16. TAFURI A, Panunzio A, Soldano A, Mazzucato G, et al
    AB0 blood groups and oncological and functional outcomes in bladder cancer patients treated with radical cystectomy.
    Arch Ital Urol Androl. 2022;94:428-433.
    PubMed    
    Abstract available

  17. LORUSSO V, Doisy L, Granata AM, Gregori A, et al
    Could we safely omit a Repeat Transurethral Resection of the Bladder (re-TURB) after Hexaminolevulinate Photodynamic Diagnostics (PDD)-TURB?
    Arch Ital Urol Androl. 2022;94:424-427.
    PubMed    
    Abstract available

  18. KATSIMPERIS S, Tzelves L, Bellos T, Angelopoulos P, et al
    Diagnosis and management of intradiverticular bladder tumours: A pooled analysis of 498 cases.
    Arch Ital Urol Androl. 2022;94:486-491.
    PubMed    
    Abstract available

  19. CHEN D, Luo Z, Ye C, Luo Q, et al
    Constructing and validating nomograms to predict risk and prognostic factors of distant metastasis in urothelial bladder cancer patients: a population-based retrospective study.
    BMC Urol. 2022;22:212.
    PubMed    
    Abstract available

  20. DO MH, Thanh HD, To PK, Kim MS, et al
    CD46 protects the bladder cancer cells from cetuximab-mediated cytotoxicity.
    Sci Rep. 2022;12:22420.
    PubMed    
    Abstract available

  21. WANG F, Xiang YS, Wu P, Shen AJ, et al
    Evaluation of amide proton transfer imaging for bladder cancer histopathologic features: A comparative study with diffusion- weighted imaging.
    Eur J Radiol. 2022;159:110664.
    PubMed    
    Abstract available

  22. GINSBURG KB, Bell S, Bukavina L, Schober JP, et al
    The Phenomenon of "Therapeutic" Nodal Yield at Cystectomy for Bladder Cancer: Do Not Discount the Will Rogers Effect.
    Eur Urol Open Sci. 2022;47:43-47.
    PubMed    
    Abstract available

  23. AL HUSSEIN AL AWAMLH B, Chang SS
    Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer.
    Curr Oncol Rep. 2022 Dec 26:1-9. doi: 10.1007/s11912-022-01350.
    PubMed    
    Abstract available

  24. GUPTA R, Mahajan M, Sharma P, Bhardwaj S, et al
    Application of Vesical Imaging-Reporting and Data System in Evaluation of Urinary Bladder Cancer Using Multiparametric Magnetic Resonance Imaging: A Hospital-Based Cross-Sectional Study.
    Avicenna J Med. 2022;12:162-168.
    PubMed    
    Abstract available

  25. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    MNS16A VNTR polymorphic sequence variations of the TERT gene and bladder cancer: Correspondence.
    Curr Urol. 2022;16:116.
    PubMed    


  26. ZHANG X, Zhang Y, Zhao L, Wang J, et al
    Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer.
    Front Immunol. 2022;13:1014638.
    PubMed    
    Abstract available

  27. MARTIN R, Renouf T, Rigby J, Hafeez S, et al
    Female sexual function in bladder cancer: A review of the evidence.
    BJUI Compass. 2022;4:5-23.
    PubMed    
    Abstract available

  28. DU X, Zhao X, Tang Y, Tang W, et al
    Construction of Pyroptosis-Related Prognostic and Immune Infiltration Signature in Bladder Cancer.
    Dis Markers. 2022;2022:6429993.
    PubMed    
    Abstract available

  29. TAO Y, Li X, Zhang Y, He L, et al
    TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics study.
    Front Genet. 2022;13:1057302.
    PubMed    
    Abstract available

  30. LI S, Chen R, Raj A, Xue N, et al
    Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer.
    Front Oncol. 2022;12:1001843.
    PubMed    
    Abstract available

  31. ESTESO G, Felgueres MJ, Garcia-Jimenez AF, Reyburn-Vales C, et al
    BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and gammadelta T-cells that can be further expanded in vitro.
    Oncoimmunology. 2022;12:2160094.
    PubMed    
    Abstract available

  32. GAO F, Wang J, Yu Y, Yan J, et al
    Comprehensive optimization of urinary exfoliated tumor cells tests in bladder cancer with a promising microfluidic platform.
    Cancer Med. 2022 Dec 25. doi: 10.1002/cam4.5481.
    PubMed    
    Abstract available

  33. SALARI A, Ghahari M, Nowroozi A, Ghahari P, et al
    Log Odds of Positive Lymph Nodes (LODDS) as an Independent Predictor of Overall Survival Following Radical Cystectomy in Urothelial Bladder Cancer: Time to Rethink Conventional Node Staging.
    Clin Genitourin Cancer. 2022 Dec 7:S1558-7673(22)00259.
    PubMed    
    Abstract available

  34. OSSOLINSKI K, Ruman T, Ossolinski T, Ossolinska A, et al
    Monoisotopic silver nanoparticles-based mass spectrometry imaging of human bladder cancer tissue: Biomarker discovery.
    Adv Med Sci. 2022;68:38-45.
    PubMed    
    Abstract available

  35. AKSAKALLI T, Kozubaev B, Yapanoglu T, Utlu A, et al
    Bladder paraganglioma treated with open partial cystectomy: a case report.
    J Med Case Rep. 2022;16:479.
    PubMed    
    Abstract available

  36. LAI S, Wu P, Liu S, Seery S, et al
    Presence of secondary bladder cancer following radical nephroureterectomy for upper tract urothelial carcinoma: characteristics, risk factors, and predictive value.
    BMC Urol. 2022;22:211.
    PubMed    
    Abstract available

  37. XV Y, Qiu M, Liu Z, Xiao M, et al
    Development of a 7-miRNA prognostic signature for patients with bladder cancer.
    Aging (Albany NY). 2022;14.
    PubMed    
    Abstract available

  38. ZHOU W, Dang L, Chong C, Cheng X, et al
    Ureteral tumor with morphological features analogous to phyllodes tumor: a unique case with concomitant urothelial carcinoma.
    Diagn Pathol. 2022;17:94.
    PubMed    
    Abstract available

  39. WARRICK JI, Hu W, Yamashita H, Walter V, et al
    Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.
    Nat Commun. 2022;13:7920.
    PubMed    


  40. KARIM NA, Ullah A, Wang H, Shoukier M, et al
    A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.
    Curr Oncol. 2022;29:9461-9473.
    PubMed    
    Abstract available

  41. LIU K, Zhao H, Alvarez-Maestro M, Gravas S, et al
    Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract.
    Curr Oncol. 2022;29:9284-9293.
    PubMed    
    Abstract available

  42. YAMASAKI H, Uematsu Y, Okano K, Ichikawa M, et al
    Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs.
    In Vitro Cell Dev Biol Anim. 2022;58:898-911.
    PubMed    
    Abstract available

  43. MURUGESAN K, Necchi A, Burn TC, Gjoerup O, et al
    Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
    ESMO Open. 2022;7:100641.
    PubMed    
    Abstract available

  44. BITARAF M, Muhammadnejad S, Azimzadeh A, Tanourlouee SB, et al
    Evaluation of direct intramural injection to the bladder wall as a method for developing orthotopic tumor models.
    Animal Model Exp Med. 2022;5:575-581.
    PubMed    
    Abstract available

  45. HE J, Dong C, Zhang H, Jiang Y, et al
    The oncogenic role of TFAP2A in bladder urothelial carcinoma via a novel long noncoding RNA TPRG1-AS1/DNMT3A/CRTAC1 axis.
    Cell Signal. 2023;102:110527.
    PubMed    
    Abstract available

  46. BUBE SH, Brix R, Christensen MB, Thostrup M, et al
    Surgical experience is predictive for bladder tumour resection quality.
    Scand J Urol. 2022;56.
    PubMed    
    Abstract available

  47. MAULHARDT H, Verco S, Baltezor M, Marin A, et al
    Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies.
    Drug Deliv Transl Res. 2023;13:503-519.
    PubMed    
    Abstract available

  48. MALM C, Jaremko G, Brehmer M
    S-phase - an independent prognostic marker in upper tract urothelial carcinoma.
    Scand J Urol. 2022;56.
    PubMed    
    Abstract available

  49. MERCIER BD, Castro DV, Pal SK
    Defining the Mycobiome in Bladder Cancer.
    Eur Urol Open Sci. 2022;48:70-71.
    PubMed    


  50. NAKAMURA R, Hasegawa G, Ohashi K, Hashimoto T, et al
    Primary lung cancer treatable with radical resection after complete remission with pembrolizumab therapy following gemcitabine and carboplatin chemotherapy for multiple metastases of bladder cancer.
    IJU Case Rep. 2022;6:85-88.
    PubMed    
    Abstract available

  51. HAYAKAWA N, Kikuchi E
    A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer.
    IJU Case Rep. 2022;6:5-7.
    PubMed    
    Abstract available

  52. LI K, Yao T, Wang Z
    lncRNA-mediated ceRNA network in bladder cancer.
    Noncoding RNA Res. 2022;8:135-145.
    PubMed    
    Abstract available

  53. OSSOLINSKI K, Ruman T, Copie V, Tripet BP, et al
    Metabolomic and elemental profiling of blood serum in bladder cancer.
    J Pharm Anal. 2022;12:889-900.
    PubMed    
    Abstract available

  54. ZHANG P, Wu G, Zhang D, Lai WF, et al
    Mechanisms and strategies to enhance penetration during intravesical drug therapy for bladder cancer.
    J Control Release. 2023 Jan 2:S0168-3659(23)00001.
    PubMed    
    Abstract available

  55. MORE SL, Fung ES, Mathis C, Schulte AM, et al
    Dermal exposure and hair dye: Assessing potential bladder cancer risk from permanent hair dye.
    Regul Toxicol Pharmacol. 2023 Jan 2:105331. doi: 10.1016/j.yrtph.2022.105331.
    PubMed    
    Abstract available

  56. DENG X, Liu X, Hu B, Liu J, et al
    Upregulation of MTHFD2 is associated with PD‑L1 activation in bladder cancer via the PI3K/AKT pathway.
    Int J Mol Med. 2023;51:14.
    PubMed    
    Abstract available

  57. KOSHKIN VS, Almassi N, Aragon-Ching JB
    Editorial: Radical cystectomy in bladder cancer patients.
    Front Oncol. 2022;12:1113112.
    PubMed    


  58. HAGGSTROM C, Hagberg O, Gardmark T, Aljabery F, et al
    Cohort profile: Bladder Cancer Data Base Sweden (BladderBaSe) 2.0.
    BMJ Open. 2022;12:e064898.
    PubMed    
    Abstract available

  59. MASONE MC
    A CAF subcluster regulates bladder cancer stemness.
    Nat Rev Urol. 2023 Jan 4. doi: 10.1038/s41585-022-00713.
    PubMed    


  60. MOLONY RD, Wu CH, Lee YF
    E-liquid exposure induces bladder cancer cells to release extracellular vesicles that promote non-malignant urothelial cell transformation.
    Sci Rep. 2023;13:142.
    PubMed    
    Abstract available

  61. LI G, Wu S, Chen W, Duan X, et al
    Designing Intelligent Nanomaterials to Achieve Highly Sensitive Diagnoses and Multimodality Therapy of Bladder Cancer.
    Small Methods. 2023 Jan 4:e2201313. doi: 10.1002/smtd.202201313.
    PubMed    
    Abstract available

  62. DAWID DE VERA MT, Prieto Cuadra JD, Alvarez Perez M, Garrido-Aranda A, et al
    PD-L1 immunoexpression and molecular characterization of histological subtypes in urothelial carcinoma.
    Rev Esp Patol. 2023;56:10-20.
    PubMed    
    Abstract available

  63. ZHANG Y, Wang Z, Yang X, Zhao Q, et al
    The influence of serum sodium concentration on prognosis in patients with urothelial carcinoma treated by radical cystectomy.
    Medicine (Baltimore). 2022;101:e31973.
    PubMed    
    Abstract available

  64. SHIBATA T, Takata E, Sakamoto J, Shioya A, et al
    A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin (BCG-CWS) for cervical cancer.
    Medicine (Baltimore). 2022;101:e32481.
    PubMed    
    Abstract available

  65. XIANG X, Guo Y, Chen Z, Zhang F, et al
    A prognostic risk prediction model based on ferroptosis-related long non-coding RNAs in bladder cancer: A bulk RNA-seq research and scRNA-seq validation.
    Medicine (Baltimore). 2022;101:e32558.
    PubMed    
    Abstract available

  66. FENG F, Zhong YX, Huang JH, Lin FX, et al
    Identifying stage-associated hub genes in bladder cancer via weighted gene co-expression network and robust rank aggregation analyses.
    Medicine (Baltimore). 2022;101:e32318.
    PubMed    
    Abstract available

  67. CHHAYA S, Watts I, Ng K, Mustapha R, et al
    Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer.
    Oncol Ther. 2023 Jan 3. doi: 10.1007/s40487-022-00218.
    PubMed    
    Abstract available

  68. MONTEIRO-REIS S, Miranda-Goncalves V, Guimaraes-Teixeira C, Martins-Lima C, et al
    Vimentin epigenetic deregulation in Bladder Cancer associates with acquisition of invasive and metastatic phenotype through epithelial-to-mesenchymal transition.
    Int J Biol Sci. 2023;19:1-12.
    PubMed    
    Abstract available

  69. SHIMIZU T, Kobayashi Y, Fujiyoshi K, Yato Y, et al
    Tuberculous spondylitis following intravesical Bacillus Calmette-Guerin therapy for bladder cancer surgically treated through the anterior approach.
    BMJ Case Rep. 2022;15:e251075.
    PubMed    
    Abstract available

  70. SAPONARO M, Flottmann S, Eckstein M, Hommerding O, et al
    CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression.
    Sci Rep. 2023;13:73.
    PubMed    
    Abstract available

  71. ICHIHASI A, Inamoto T, Uchimoto T, Nakamura KO, et al
    Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder Cancer.
    In Vivo. 2023;37:143-148.
    PubMed    
    Abstract available

  72. SOOROJEBALLY Y, Neuzillet Y, Roumiguie M, Lamy PJ, et al
    Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
    World J Urol. 2023 Jan 2. doi: 10.1007/s00345-022-04253.
    PubMed    
    Abstract available

  73. CHEN Z, Qin C, Wang G, Shang D, et al
    A tumor microenvironment preoperative nomogram for prediction of lymph node metastasis in bladder cancer.
    Front Oncol. 2022;12:1099965.
    PubMed    
    Abstract available

  74. NONATO MB, Moraes RS, Bandeira Herenio YM, Nunes TF, et al
    Management of a Giant Urinary Bladder Clot with Intravesical Thrombolysis.
    J Vasc Interv Radiol. 2023;34:154-155.
    PubMed    


  75. CHENG W, Zhou Y, Chu X, Huang S, et al
    Effect of intravesical mitomycin compared with gemcitabine on the treatment non-muscle invasive bladder cancer: A meta-analysis.
    Actas Urol Esp (Engl Ed). 2022 Dec 28:S2173-5786(22)00142.
    PubMed    
    Abstract available

  76. YAMASHITA T, Higashi M, Sugiyama H, Morozumi M, et al
    Cancer antigen 125 expression enhances the gemcitabine/cisplatin-resistant tumor microenvironment in bladder cancer.
    Am J Pathol. 2022 Dec 28:S0002-9440(22)00419.
    PubMed    
    Abstract available

  77. ZHOU M, Yang B, Zhou S, Yu P, et al
    Will repeat resection after initial transurethral en bloc resection benefit patients with high-risk non-muscle-invasive bladder cancer? A propensity score matching analysis.
    J Cancer Res Clin Oncol. 2022 Dec 31. doi: 10.1007/s00432-022-04564.
    PubMed    
    Abstract available

  78. NISHIMURA N, Miyake M, Miyamoto T, Tomizawa M, et al
    The Japanese health care system-based cost-effectiveness of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer.
    Jpn J Clin Oncol. 2022 Dec 30:hyac203. doi: 10.1093.
    PubMed    
    Abstract available

  79. XU Y, Tong Y, Lei Z, Zhu J, et al
    Abietic acid induces ferroptosis via the activation of the HO-1 pathway in bladder cancer cells.
    Biomed Pharmacother. 2022;158:114154.
    PubMed    
    Abstract available

  80. VAN DER FELS CAM, Leliveld A, Buikema H, van den Heuvel MC, et al
    VEGF, EGFR and PSMA as possible imaging targets of lymph node metastases of urothelial carcinoma of the bladder.
    BMC Urol. 2022;22:213.
    PubMed    
    Abstract available

  81. LEVY JJ, Liu X, Marotti JD, Kerr DA, et al
    Uncovering additional predictors of urothelial carcinoma from voided urothelial cell clusters through a deep learning-based image preprocessing technique.
    Cancer Cytopathol. 2023;131:19-29.
    PubMed    
    Abstract available

  82. TANG L, Wang S, Wang Y, Li K, et al
    LncRNA-UCA1 regulates lung adenocarcinoma progression through competitive binding to miR-383.
    Cell Cycle. 2023;22:213-228.
    PubMed    
    Abstract available

  83. SASAKI Y, Takahashi M, Hashimoto K, Fukuta K, et al
    Efficacy of the Mercedes-Benz closure technique for vaginal reconstruction in female robot-assisted radical cystectomy.
    Asian J Endosc Surg. 2023;16:23-27.
    PubMed    
    Abstract available

  84. NAYA Y, Takaha N, Hayashi I, Mori M, et al
    Preliminary study of the safety of acrinol in probe-based confocal laser endomicroscopy during transurethral resection of bladder tumors.
    Asian J Endosc Surg. 2023;16:143-146.
    PubMed    
    Abstract available

  85. GARCIA JH, Morshed RA, Chung J, Millares Chavez MA, et al
    Factors associated with preoperative and postoperative seizures in patients undergoing resection of brain metastases.
    J Neurosurg. 2022 Apr 29:1-8. doi: 10.3171/2022.3.JNS212285.
    PubMed    
    Abstract available

  86. MAIBOM SL, Joensen UN, Aasvang EK, Rohrsted M, et al
    Robot-assisted laparoscopic radical cystectomy with intracorporeal ileal conduit diversion versus open radical cystectomy with ileal conduit for bladder cancer in an ERAS setup (BORARC): protocol for a single-centre, double-blinded, randomised feasibi
    Pilot Feasibility Stud. 2023;9:7.
    PubMed    
    Abstract available

  87. CHEN CC, Fa YC, Kuo YY, Liu YC, et al
    Thiolated Mesoporous Silica Nanoparticles as an Immunoadjuvant to Enhance Efficacy of Intravesical Chemotherapy for Bladder Cancer.
    Adv Sci (Weinh). 2023 Jan 13:e2204643. doi: 10.1002/advs.202204643.
    PubMed    
    Abstract available

  88. LIU B, Su J, Fan B, Ni X, et al
    High expression of KIF20A in bladder cancer as a potential prognostic target for poor survival of renal cell carcinoma.
    Medicine (Baltimore). 2023;102:e32667.
    PubMed    
    Abstract available

  89. MORIBATA Y, Kurata Y, Nishio M, Kido A, et al
    Automatic segmentation of bladder cancer on MRI using a convolutional neural network and reproducibility of radiomics features: a two-center study.
    Sci Rep. 2023;13:628.
    PubMed    
    Abstract available

  90. DOHERTY N, Cardwell CR, Murchie P, Hill C, et al
    5-Alpha Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2023 Jan 12:EPI-22-1109.
    PubMed    
    Abstract available

  91. LIU C, Wang XL, Shen EC, Wang BZ, et al
    Bioinformatics analysis of prognosis and immune microenvironment of immunological cell death-related gemcitabine-resistance genes in bladder cancer.
    Transl Androl Urol. 2022;11:1715-1728.
    PubMed    
    Abstract available

  92. TOMIYAMA E, Fujita K, Hashimoto M, Adomi S, et al
    Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in the era of targeted therapy: a narrative review.
    Transl Androl Urol. 2022;11:1747-1761.
    PubMed    
    Abstract available

  93. JIA C, Zhang X, Qu T, Wu X, et al
    Depletion of PSMD14 suppresses bladder cancer proliferation by regulating GPX4.
    PeerJ. 2023;11:e14654.
    PubMed    
    Abstract available

  94. RIVEROS C, Chalfant V, Elshafei A, Bandyk M, et al
    Does care fragmentation in patients with bladder cancer lead to worse outcomes?
    Urol Oncol. 2023 Jan 9:S1078-1439(22)00432-X. doi: 10.1016/j.urolonc.2022.
    PubMed    
    Abstract available

  95. AFFERI L, Gallioli A, Del Giudice F, Pradere B, et al
    Comment on "Neoadjuvant systemic therapy in patients undergoing nephroureterectomy for urothelial cancer: a multidisciplinary systematic review and critical analysis" on behalf of the Young Academic Urologists - Urothelial Cancer Working Group.
    Minerva Urol Nephrol. 2022;74:813-815.
    PubMed    


  96. LIM S, Park JH, Chang H
    Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model.
    Investig Clin Urol. 2023;64:74-81.
    PubMed    
    Abstract available

  97. MEHTA P, Sinha S, Kashid S, Chakraborty D, et al
    Exploring Texture Analysis to Optimize Bladder Preservation in Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2022 Nov 18:S1558-7673(22)00241.
    PubMed    
    Abstract available

  98. HARA S, Honda M, Kawaharada A, Nakazono M, et al
    [A Case of Metastatic Ureteral Cancer Treated with Pembrolizumab without Relapse of Ocular Myasthenia Gravis].
    Hinyokika Kiyo. 2022;68:377-383.
    PubMed    
    Abstract available

  99. BAMIAS A, Merseburger A, Loriot Y, James N, et al
    New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
    J Immunother Cancer. 2023;11:e005977.
    PubMed    
    Abstract available

  100. WEI X, Wang B, Wu Z, Yang X, et al
    WD repeat protein 54-mediator of ErbB2-driven cell motility 1 axis promotes bladder cancer tumorigenesis and metastasis and impairs chemosensitivity.
    Cancer Lett. 2023 Jan 7:216058. doi: 10.1016/j.canlet.2023.216058.
    PubMed    
    Abstract available

  101. ZHOU H, Huang J, Wang F
    Increased transcription of hsa_circ_0000644 upon RUNX family transcription factor 3 downregulation participates in the malignant development of bladder cancer.
    Cell Signal. 2023 Jan 7:110590. doi: 10.1016/j.cellsig.2023.110590.
    PubMed    
    Abstract available

  102. YU ZY, Yan L, Wang HK, Hang G, et al
    Bladder triangle amyloidosis: A case report and literature review.
    Medicine (Baltimore). 2022;101:e32179.
    PubMed    
    Abstract available

  103. AIZAT SABRI I, Yusof MR, Jagwani AV, Fahmy O, et al
    [A rare case of bladder leiomyoma in pregnancy: a case report].
    Urologiia. 2022;:118-121.
    PubMed    
    Abstract available

  104. LIMA NF JR, Sampaio LAF, Xavier CB, Mattedi RL, et al
    Complete Response to Sequential Human Epidermal Growth Factor Receptor 2-Targeted Strategies in a Heavily Pretreated Patient With Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Bladder Cancer.
    JCO Precis Oncol. 2023;7:e2200414.
    PubMed    


  105. FEIERTAG N, Barry E, Abramson M, Park JY, et al
    Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non-muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2022 Dec 23:S1558-7673(22)00262.
    PubMed    
    Abstract available

  106. WANG W, Hua S, Li J, Zhao J, et al
    Tumour microenvironment landscape and immunotherapy response in bladder cancer decoded by stromal MOXD1 based on copper-related genes signature.
    Front Oncol. 2022;12:1081091.
    PubMed    
    Abstract available

  107. SHI C, Zhang L, Chen D, Wei H, et al
    Prognostic value of TMEM59L and its genomic and immunological characteristics in cancer.
    Front Immunol. 2022;13:1054157.
    PubMed    
    Abstract available

  108. MOUSA FA, Jasim HA, Shakir F
    A Prognostic Impact of Interleukin 17 (IL-17) as an Immune-Marker in Patients with Bladder Cancer.
    Arch Razi Inst. 2022;77:1059-1065.
    PubMed    
    Abstract available

  109. ZHU Y, Zuo L, Xiong H, Li S, et al
    CircHGS enhances the progression of bladder cancer by regulating the miR-513a-5p/VEGFC axis and activating the AKT/mTOR signaling pathway.
    Cell Cycle. 2023 Jan 8:1-20. doi: 10.1080/15384101.2022.2164454.
    PubMed    
    Abstract available

  110. SPAGNUOLO C, Moccia S, Tedesco I, Crescente G, et al
    Phenolic Extract from Extra Virgin Olive Oil Induces Different Anti-Proliferative Pathways in Human Bladder Cancer Cell Lines.
    Nutrients. 2022;15:182.
    PubMed    
    Abstract available

  111. LI Z, Qi N, Gao Z, Ding L, et al
    How to Perform Intravesical Chemotherapy after Second TURBT for Non-Muscle-Invasive Bladder Cancer: A Single-Center Experience.
    J Clin Med. 2022;12:169.
    PubMed    
    Abstract available

  112. KUO MY, Yang WT, Ho YJ, Chang GM, et al
    Hispolon Methyl Ether, a Hispolon Analog, Suppresses the SRC/STAT3/Survivin Signaling Axis to Induce Cytotoxicity in Human Urinary Bladder Transitional Carcinoma Cell Lines.
    Int J Mol Sci. 2022;24:138.
    PubMed    
    Abstract available

  113. DOMINGOS-PEREIRA S, Sathiyanadan K, Polak L, Haefliger JA, et al
    Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.
    Int J Mol Sci. 2022;24:123.
    PubMed    
    Abstract available

  114. GOUTAS D, Palamaris K, Stofas A, Politakis N, et al
    Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 Expression.
    Cancers (Basel). 2022;15:188.
    PubMed    
    Abstract available

  115. MIYAGI H, Kwenda E, Ramnaraign BH, Chatzkel JA, et al
    Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2022;15:168.
    PubMed    
    Abstract available

  116. ZHANG W, Yang F, Zheng Z, Li C, et al
    Sulfatase 2 Affects Polarization of M2 Macrophages through the IL-8/JAK2/STAT3 Pathway in Bladder Cancer.
    Cancers (Basel). 2022;15:131.
    PubMed    
    Abstract available

  117. SMITH V, Mukherjee D, Tsakiroglou AM, Baker A, et al
    Low CD8 T Cell Counts Predict Benefit from Hypoxia-Modifying Therapy in Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2022;15:41.
    PubMed    
    Abstract available

  118. GWON YN, Park JJ, Lee KS, Lee KH, et al
    Microbiome in Bladder Cancer: A Systematic Review.
    Diagnostics (Basel). 2022;13:84.
    PubMed    
    Abstract available

  119. CHEN S, Jian Y, Tang W, Gu H, et al
    Replacement of long-segment ureteral defect with tapered demucosalized ileum: medium-term outcomes of 4 patients.
    BMC Urol. 2023;23:7.
    PubMed    
    Abstract available

  120. LI W, Cheng M, Hu P, Jiang L, et al
    Prognosis of male lung cancer patients with urinary cancer: a study from a national population-based analysis.
    Sci Rep. 2023;13:283.
    PubMed    
    Abstract available

  121. TIAN C, Liu J, An L, Hong Y, et al
    Prognostic nomogram for overall survival in upper urinary tract urothelial carcinoma (UTUC) patients treated with chemotherapy: a SEER-based retrospective cohort study.
    BMC Urol. 2023;23:2.
    PubMed    
    Abstract available

  122. MASONE MC
    The prognostic role of stroma in UTUC.
    Nat Rev Urol. 2023;20:7.
    PubMed    


  123. MASONE MC
    A non-invasive assay for UTUC diagnosis.
    Nat Rev Urol. 2023;20:8.
    PubMed    


  124. KOTERAZAWA S, Kanno T, Kobori G, Ito K, et al
    Clinical outcomes following laparoscopic radical nephroureterectomy in octogenarians.
    Int J Clin Oncol. 2023;28:155-162.
    PubMed    
    Abstract available

  125. YU SL, Hsiao YJ, Cooper WA, Choi YL, et al
    The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
    Pathology. 2023;55:19-30.
    PubMed    
    Abstract available

  126. TOMITA Y, Kobayashi K, Kimura G, Oya M, et al
    Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.
    Jpn J Clin Oncol. 2023;53:16-25.
    PubMed    
    Abstract available

  127. LENNARTZ M, Ullmann VS, Gorbokon N, Uhlig R, et al
    Cytokeratin 13 (CK13) expression in cancer: a tissue microarray study on 10,439 tumors.
    APMIS. 2023;131:77-91.
    PubMed    
    Abstract available

  128. HOLMES A, O'Kane D, Wombwell A, Grills R, et al
    Clinical Utility of a Single-Use Flexible Cystoscope Compared with a Standard Reusable Device: A Randomized Noninferiority Study.
    J Endourol. 2023;37:80-84.
    PubMed    
    Abstract available

  129. NAKAGAWA T, Shigehara K, Kato Y, Kawaguchi S, et al
    Are bladder washing samples suitable for investigation of HPV infection in urinary bladder? Comparison in HPV prevalence between urine and washing samples.
    J Med Virol. 2023;95:e28110.
    PubMed    
    Abstract available

  130. PENDELA VS, Said B, Kudaravalli P, Chhabria M, et al
    Interstitial Pneumonitis-A Newly Recognized Consequence of Intravesical Gemcitabine Therapy.
    Am J Ther. 2022;29:e752-e754.
    PubMed    


  131. LIN W, Pan X, Zhang C, Ye B, et al
    Impact of Age at Diagnosis of Bladder Cancer on Survival: A Surveillance, Epidemiology, and End Results-Based Study 2004-2015.
    Cancer Control. 2023;30:10732748231152322.
    PubMed    
    Abstract available

  132. YUKSEL O, Tosun C, Gumrukcu G, Tokuc E, et al
    What is the role of CellDetect((R)) in detecting and monitoring bladder cancer?
    Urologia. 2023 Jan 20:3915603221150036. doi: 10.1177/03915603221150036.
    PubMed    
    Abstract available

  133. WU J, Wang X, Xu H, Tian J, et al
    Bioinformatics analysis of the correlation between m6A RNA methylation regulators and the immune infiltration and prognosis of bladder cancer.
    Ann Transl Med. 2022;10:1386.
    PubMed    
    Abstract available

  134. NAGATA M, Ishizaka K, Asano T
    CD169(+) Macrophages Residing in the Draining Lymph Nodes and Infiltrating the Tumor Play Opposite Roles in the Pathogenesis of Bladder Cancer.
    Res Rep Urol. 2023;15:1-7.
    PubMed    
    Abstract available

  135. WARLI SM, Prapiska FF, Siregar DIS, Wijaya WS, et al
    Association Between Interleukin-6 Levels and Lymph Node Metastasis in Bladder Cancer Patients.
    World J Oncol. 2022;13:365-369.
    PubMed    
    Abstract available

  136. CHAUHAN PS, Shiang A, Alahi I, Sundby RT, et al
    Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients.
    NPJ Precis Oncol. 2023;7:6.
    PubMed    
    Abstract available

  137. BAXTER L, Gordon NS, Ott S, Wang J, et al
    Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection.
    Sci Rep. 2023;13:1060.
    PubMed    
    Abstract available

  138. WU X, Xu Q, Li T, Wei Y, et al
    Bladder Cancer Progression Is Suppressed Through the Heart and Neural Crest Derivatives Expressed 2-Antisense RNA 1/microRNA-93-5p/Defective in Cullin Neddylation 1 Domain Containing 3 Axis.
    Appl Biochem Biotechnol. 2023 Jan 19. doi: 10.1007/s12010-022-04295.
    PubMed    
    Abstract available

  139. ZHANG W, Zhou B, Deng J, Han G, et al
    Retrospective analysis of 1470-/980-nm dual-wavelength laser en bloc resection versus transurethral resection of bladder tumor for primary non-muscle-invasive bladder cancer.
    Lasers Med Sci. 2023;38:44.
    PubMed    
    Abstract available

  140. YADAV K, Agarwal P, Kumar M, Gupta S, et al
    Immunohistochemical appraisal of epithelial mesenchymal transition type III in gall bladder cancer.
    Indian J Pathol Microbiol. 2023;66:44-53.
    PubMed    
    Abstract available

  141. WANG S, Yu Z, Du P, Cao Y, et al
    Combination of hyperthermia and intravesical chemotherapy for the treatment of pT1 stage bladder cancer: A retrospectively clinical study.
    Asia Pac J Clin Oncol. 2023 Jan 19. doi: 10.1111/ajco.13931.
    PubMed    
    Abstract available

  142. GROBET-JEANDIN E, Pinar U, Parra J, Roupret M, et al
    Health-related quality of life after curative treatment for muscle-invasive bladder cancer.
    Nat Rev Urol. 2023 Jan 18. doi: 10.1038/s41585-022-00693.
    PubMed    
    Abstract available

  143. FU X, Yu G, Guo Y
    [Expression pattern of the histone lysine demethylase family and its potential role in bladder cancer: a multi-omics analysis].
    Nan Fang Yi Ke Da Xue Xue Bao. 2022;42:1822-1831.
    PubMed    
    Abstract available

  144. SELIM MS, Kassem AB, El-Bassiouny NA, Salahuddin A, et al
    Polymorphic renal transporters and cisplatin's toxicity in urinary bladder cancer patients: current perspectives and future directions.
    Med Oncol. 2023;40:80.
    PubMed    
    Abstract available

  145. WANG Y, Zhang W, Xiao W, Chen S, et al
    Feasibility of Early Evaluation for the Recurrence of Bladder Cancer after Trans-Urethral Resection: A Comparison between Magnetic Resonance Imaging and Multidetector Computed Tomography.
    Tomography. 2022;9:25-35.
    PubMed    
    Abstract available

  146. RAMMANT E, Fox L, Beyer K, Aaronson NK, et al
    The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review.
    Qual Life Res. 2023 Jan 17. doi: 10.1007/s11136-022-03335.
    PubMed    
    Abstract available

  147. RUBIN R
    New Gene Therapy for Certain Bladder Cancers.
    JAMA. 2023;329:201.
    PubMed    


  148. GU J, He Z, Chen Z, Wu H, et al
    Efficacy and safety of 2-micron laser versus conventional trans-urethral resection of bladder tumor for non-muscle-invasive bladder tumor: A systematic review and meta-analysis.
    J Cancer Res Ther. 2022;18:1894-1902.
    PubMed    
    Abstract available

  149. JI J, Yao Y, Guan F, Sun L, et al
    Efficacy and adverse reactions of intra-arterial chemotherapy in patients with bladder cancer: A systematic review and meta-analysis.
    J Cancer Res Ther. 2022;18:1884-1893.
    PubMed    
    Abstract available

  150. RAADABADI M, Daroudi R, Zendehdel K, Haghdoost AA, et al
    Direct and indirect medical costs of bladder cancer in Iran.
    Cost Eff Resour Alloc. 2023;21:5.
    PubMed    
    Abstract available

  151. LUO M, Zhang Y, Xu Z, Lv S, et al
    Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation.
    Mol Med. 2023;29:7.
    PubMed    
    Abstract available

  152. CARVALHO LB, Capelo JL, Lodeiro C, Dhir R, et al
    Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics.
    Commun Med (Lond). 2023;3:8.
    PubMed    
    Abstract available

  153. SECHER MS, Hyldgaard J, Jensen JB
    The association between gender, stage and prognosis in bladder cancer patients undergoing radical cystectomy.
    Scand J Urol. 2023 Jan 16:1-5. doi: 10.1080/21681805.2023.2166103.
    PubMed    
    Abstract available

  154. LIU W, Xu Y, Bai S, Liao L, et al
    Bioinformatics analysis of key biomarkers for bladder cancer.
    Biomed Rep. 2022;18:14.
    PubMed    
    Abstract available

  155. VILLANUEVA H, Wells GA, Miller MT, Villanueva M, et al
    Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model.
    Heliyon. 2022;8:e12570.
    PubMed    
    Abstract available

  156. SHEFER HK, Masarwe I, Bejar J, Naamnih LH, et al
    Performance of CellDetect for detection of bladder cancer: Comparison with urine cytology and UroVysion.
    Urol Oncol. 2023 Jan 13:S1078-1439(22)00497.
    PubMed    
    Abstract available

  157. GOEBELL PJ, Kamat AM, Black PC, Dyrskjot L, et al
    Editorial: Cutting edge basic and clinical bladder cancer research - the IBCN updates.
    Urol Oncol. 2023 Jan 12:S1078-1439(22)00498.
    PubMed    


  158. WU Q, Chen P, Li J, Lin Z, et al
    Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin alpha5/beta1-FAK/Src axis: A novel strategy for drug application.
    Pharmacol Res. 2023;188:106654.
    PubMed    
    Abstract available

  159. WU J, Jin S, Gu C, Wei Y, et al
    Inherited mutations in Chinese patients with upper tract urothelial carcinoma.
    Cell Rep Med. 2023;4:100883.
    PubMed    
    Abstract available

  160. ORSI DL, Ferrara SJ, Siegel S, Friberg A, et al
    Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
    Bioorg Med Chem. 2022;78:117130.
    PubMed    
    Abstract available

  161. KUJDOWICZ M, Perez-Guaita D, Chlosta P, Okon K, et al
    Evaluation of grade and invasiveness of bladder urothelial carcinoma using infrared imaging and machine learning.
    Analyst. 2022 Dec 16. doi: 10.1039/d2an01583.
    PubMed    
    Abstract available

  162. PETTITT GA, Hurst CD, Khan Z, McPherson HR, et al
    Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro.
    J Pathol. 2023;259:220-232.
    PubMed    
    Abstract available

  163. HOGAN K, McKenney JK, Cox RM, Nguyen JK, et al
    Myxoid Pseudotumor Involving the Renal Sinus: Clinicopathologic Study of 33 Cases Supporting a Distinct Benign Non-neoplastic Lesion.
    Am J Surg Pathol. 2023;47:218-223.
    PubMed    
    Abstract available

  164. SHIMURA S, Matsumoto K, Ikeda M, Moroo S, et al
    A multi-institutional retrospective study of open versus laparoscopic nephroureterectomy focused on the intravesical recurrence.
    Asia Pac J Clin Oncol. 2023;19:71-78.
    PubMed    
    Abstract available

  165. ZHANG W, Yang F, Mao S, Wang R, et al
    Bladder cancer-associated microbiota: Recent advances and future perspectives.
    Heliyon. 2023;9:e13012.
    PubMed    
    Abstract available

  166. ALJABERY F, Shabo I, Saudi A, Holmbom M, et al
    The emerging role of cell cycle protein p53 expression by tumor cells and M2-macrophage infiltration in urinary bladder cancer.
    Urol Oncol. 2023 Jan 24:S1078-1439(22)00490.
    PubMed    
    Abstract available

  167. HOGLUND M, Bernardo C, Sjodahl G, Eriksson P, et al
    The Lund Taxonomy for Bladder Cancer Classification - From Gene Expression Clustering to Cancer Cell Molecular Phenotypes, and Back Again.
    J Pathol. 2023 Jan 26. doi: 10.1002/path.6062.
    PubMed    
    Abstract available

  168. WAN B, Ma N, Lu W
    Mendelian randomization investigation identified the causal relationship between body fat indexes and the risk of bladder cancer.
    PeerJ. 2023;11:e14739.
    PubMed    
    Abstract available

  169. MARTINS-LIMA C, Chianese U, Benedetti R, Altucci L, et al
    Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game?
    Front Mol Biosci. 2023;9:1070383.
    PubMed    
    Abstract available

  170. LI P, Mi Q, Yan S, Xie Y, et al
    Characterization of circSCL38A1 as a novel oncogene in bladder cancer via targeting ILF3/TGF-beta2 signaling axis.
    Cell Death Dis. 2023;14:59.
    PubMed    
    Abstract available

  171. YONG Z, Ang L, Wen-Zhang Z, Xu-Dong W, et al
    Incidental gall bladder cancer in the laparoscopic treatment and magnetic resonance imaging era: A single institution experience.
    J Minim Access Surg. 2023 Jan 9. doi: 10.4103.
    PubMed    
    Abstract available

  172. VAN PUFFELEN JH, Novakovic B, van Emst L, Kooper D, et al
    Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections.
    J Immunother Cancer. 2023;11:e005518.
    PubMed    
    Abstract available

  173. PAN J, Hong G, Zeng H, Liao C, et al
    An artificial intelligence model for the pathological diagnosis of invasion depth and histologic grade in bladder cancer.
    J Transl Med. 2023;21:42.
    PubMed    
    Abstract available

  174. JIN M, Lu S, Wu Y, Yang C, et al
    Retraction Note: Hsa_circ_0001944 promotes the growth and metastasis in bladder cancer cells by acting as a competitive endogenous RNA for miR-548.
    J Exp Clin Cancer Res. 2023;42:32.
    PubMed    


  175. LIU HP, Jia W, Kadeerhan G, Xue B, et al
    Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature.
    Transl Oncol. 2023;29:101629.
    PubMed    
    Abstract available

  176. LAI AL, Law YM
    VI-RADS in bladder cancer: Overview, pearls and pitfalls.
    Eur J Radiol. 2023;160:110666.
    PubMed    
    Abstract available

  177. SHEN C, Yan Y, Yang S, Wang Z, et al
    Construction and validation of a bladder cancer risk model based on autophagy-related genes.
    Funct Integr Genomics. 2023;23:46.
    PubMed    
    Abstract available

  178. TALWAR HS, Panwar VK, Mittal A, Kishore S, et al
    A Clinicopathological Correlation of Bladder Cancer in Young and Old Patients: Our Experience and Review of Literature.
    Indian J Surg Oncol. 2022;13:915-923.
    PubMed    
    Abstract available

  179. AND ALTERNATIVE MEDICINE EC
    Retracted: Effect of Radical Laparoscopic Surgery and Conventional Open Surgery on Surgical Outcomes, Complications, and Prognosis in Elderly Patients with Bladder Cancer.
    Evid Based Complement Alternat Med. 2023;2023:9835627.
    PubMed    
    Abstract available

  180. YU X, Luo B, Lin J, Zhu Y, et al
    Alternative splicing event associated with immunological features in bladder cancer.
    Front Oncol. 2023;12:966088.
    PubMed    
    Abstract available

  181. CAI J, Xie H, Yan Y, Huang Z, et al
    A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer.
    Front Genet. 2023;13:1082691.
    PubMed    
    Abstract available

  182. XIAO Y, Xu D, Jiang C, Huili Y, et al
    Telomere maintenance-related genes are important for survival prediction and subtype identification in bladder cancer.
    Front Genet. 2023;13:1087246.
    PubMed    
    Abstract available

  183. DENG H, Deng D, Qi T, Liu Z, et al
    An IFN-gamma-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts.
    Front Genet. 2023;13:1100317.
    PubMed    
    Abstract available

  184. TANTRAY I, Ojha R, Sharma AP
    Non-coding RNA and autophagy: Finding novel ways to improve the diagnostic management of bladder cancer.
    Front Genet. 2023;13:1051762.
    PubMed    
    Abstract available

  185. ASHRAFIZADEH M, Zarrabi A, Karimi-Maleh H, Taheriazam A, et al
    (Nano)platforms in bladder cancer therapy: Challenges and opportunities.
    Bioeng Transl Med. 2022;8:e10353.
    PubMed    
    Abstract available

  186. HAN DS, Johnson JP, Schulster ML, Shah O, et al
    Indications for and results of renal autotransplantation.
    Curr Opin Nephrol Hypertens. 2023;32:183-192.
    PubMed    
    Abstract available

  187. TANABE T, Osawa T, Hotta K, Iwami D, et al
    [TREATMENT OF BLADDER UROTHELIAL CARCINOMA WITH LUNG METASTASIS AFTER RENAL TRANSPLANTATION].
    Nihon Hinyokika Gakkai Zasshi. 2022;113:37-41.
    PubMed    
    Abstract available

  188. IMAMURA T, Miyachi S, Horiuchi E, Ikeda T, et al
    [A CASE OF PRIMARY MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA OF THE URINARY BLADDER].
    Nihon Hinyokika Gakkai Zasshi. 2022;113:28-32.
    PubMed    
    Abstract available

  189. KONDO Y, Takayama T
    [STUDY OF URINATION TREATMENT AFTER BCG INTRAVESICAL INSTILLATION THERAPY].
    Nihon Hinyokika Gakkai Zasshi. 2022;113:12-15.
    PubMed    
    Abstract available

  190. EL-MAHDY HA, Elsakka EGE, El-Husseiny AA, Ismail A, et al
    miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay - A review.
    Pathol Res Pract. 2023;242:154316.
    PubMed    
    Abstract available

  191. KOBAYASHI K, Matsuyama H, Oka S, Nakamura K, et al
    Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer.
    Photodiagnosis Photodyn Ther. 2023;41:103294.
    PubMed    
    Abstract available

  192. YU C, Wang S, Lai WF, Zhang D, et al
    The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment.
    Pharmaceutics. 2023;15:211.
    PubMed    
    Abstract available

  193. RU R, Chen G, Liang X, Cao X, et al
    Sea Cucumber Derived Triterpenoid Glycoside Frondoside A: A Potential Anti-Bladder Cancer Drug.
    Nutrients. 2023;15:378.
    PubMed    
    Abstract available

  194. NIKIC P, Dragicevic D, Jerotic D, Savic S, et al
    Polymorphisms of Antioxidant Enzymes SOD2 (rs4880) and GPX1 (rs1050450) Are Associated with Bladder Cancer Risk or Its Aggressiveness.
    Medicina (Kaunas). 2023;59:131.
    PubMed    
    Abstract available

  195. TRIFANESCU OG, Gales LN, Paun MA, Motas N, et al
    Long-Term Outcome of Patients with Stage II and III Muscle-Invasive Urothelial Bladder Cancer after Multimodality Approach. Which Is the Best Option?
    Medicina (Kaunas). 2022;59:50.
    PubMed    
    Abstract available

  196. YI L, Ai K, Li X, Li Z, et al
    Bone Metastasis in Bladder Cancer.
    J Pers Med. 2022;13:54.
    PubMed    
    Abstract available

  197. CABALLERO JM, Gili JM, Pereira JC, Gomariz A, et al
    Risk Factors Involved in the High Incidence of Bladder Cancer in an Industrialized Area in North-Eastern Spain: A Case-Control Study.
    J Clin Med. 2023;12:728.
    PubMed    
    Abstract available

  198. YANG S, Zhou H, Feng C, Xu N, et al
    Web-Based Nomograms for Overall Survival and Cancer-Specific Survival of Bladder Cancer Patients with Bone Metastasis: A Retrospective Cohort Study from SEER Database.
    J Clin Med. 2023;12:726.
    PubMed    
    Abstract available

  199. HUANG GK, Huang CC, Kang CH, Cheng YT, et al
    Genetic Interference of FGFR3 Impedes Invasion of Upper Tract Urothelial Carcinoma Cells by Alleviating RAS/MAPK Signal Activity.
    Int J Mol Sci. 2023;24:1776.
    PubMed    
    Abstract available

  200. LAZEWSKI D, Kucinska M, Potapskiy E, Kuzminska J, et al
    Enhanced Cytotoxic Activity of PEGylated Curcumin Derivatives: Synthesis, Structure-Activity Evaluation, and Biological Activity.
    Int J Mol Sci. 2023;24:1467.
    PubMed    
    Abstract available

  201. PEREZ-MONTIEL MD, Cerrato-Izaguirre D, Sanchez-Perez Y, Diaz-Chavez J, et al
    Mutational Landscape of Bladder Cancer in Mexican Patients: KMT2D Mutations and chr11q15.5 Amplifications Are Associated with Muscle Invasion.
    Int J Mol Sci. 2023;24:1092.
    PubMed    
    Abstract available

  202. DAS S, Hayden J, Sullivan T, Rieger-Christ K, et al
    The Roles of miRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment.
    Int J Mol Sci. 2023;24:964.
    PubMed    
    Abstract available

  203. VARELA M, Lopez M, Ingold M, Alem D, et al
    New Nitric Oxide-Releasing Compounds as Promising Anti-Bladder Cancer Drugs.
    Biomedicines. 2023;11:199.
    PubMed    
    Abstract available

  204. BEJRANANDA T, Saetang J, Sangkhathat S
    Molecular Subtyping in Muscle-Invasive Bladder Cancer on Predicting Survival and Response of Treatment.
    Biomedicines. 2022;11:69.
    PubMed    
    Abstract available

  205. MONTEIRO-REIS S, Ferreira JPS, Pires RA, Lobo J, et al
    Bladder Wall Stiffness after Cystectomy in Bladder Cancer Patients: A Preliminary Study.
    Cancers (Basel). 2023;15:359.
    PubMed    
    Abstract available

  206. SONG FX, Xu X, Ding H, Yu L, et al
    Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer.
    Biosensors (Basel). 2023;13:106.
    PubMed    
    Abstract available

  207. ZHANG Q, Liu S, Wang H, Xiao K, et al
    ETV4 Mediated Tumor-Associated Neutrophil Infiltration Facilitates Lymphangiogenesis and Lymphatic Metastasis of Bladder Cancer.
    Adv Sci (Weinh). 2023 Jan 20:e2205613. doi: 10.1002/advs.202205613.
    PubMed    
    Abstract available

  208. BEIJERT IJ, Hentschel AE, Brundl J, Comperat EM, et al
    Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
    Eur Urol Oncol. 2023 Jan 18:S2588-9311(23)00004.
    PubMed    
    Abstract available

  209. YEN A, Shen C, Albuquerque K
    The New Kid on the Block: Online Adaptive Radiotherapy in the Treatment of Gynecologic Cancers.
    Curr Oncol. 2023;30:865-874.
    PubMed    
    Abstract available

  210. ZALAY O, Yan M, Sigurdson S, Malone S, et al
    Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis.
    Curr Oncol. 2022;30:19-36.
    PubMed    
    Abstract available

  211. PATWARDHAN PP, Quiroga-Garza GM
    Extramammary paget disease of the penoscrotal region.
    Pathol Res Pract. 2023;241:154283.
    PubMed    
    Abstract available

  212. KANG SY, Heo YJ, Kwon GY, Lee J, et al
    Five-gene signature for the prediction of response to immune checkpoint inhibitors in patients with gastric and urothelial carcinomas.
    Pathol Res Pract. 2023;241:154233.
    PubMed    
    Abstract available

  213. MLICKA A, Mlicki P, Niewiadomski P, Zielinska W, et al
    Synergistic effect of metformin and doxorubicin on the metastatic potential of T24 cells.
    Acta Histochem. 2023;125:151975.
    PubMed    
    Abstract available

  214. HEROUT R, Baunacke M, Flegar L, Borkowetz A, et al
    Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019.
    World J Urol. 2023;41:127-133.
    PubMed    
    Abstract available

  215. GUO B, Wang Y, Liu W, Zhang S, et al
    Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Clin Transl Oncol. 2023;25:535-554.
    PubMed    
    Abstract available

  216. HUANG L, Shao W, Wang X, Li F, et al
    TBX3 stimulates proliferation and stem cell self-renewal in bladder carcinoma.
    Histol Histopathol. 2023;38:65-72.
    PubMed    
    Abstract available

  217. KULLMANN F, Strissel PL, Strick R, Stoehr R, et al
    Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort.
    J Clin Pathol. 2023;76:126-132.
    PubMed    
    Abstract available

  218. XIANG L, Zeng Q, Liu J, Xiao M, et al
    MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis.
    Sci Bull (Beijing). 2021;66:1773-1788.
    PubMed    
    Abstract available

  219. KLEANTHOUS K, Alexopoulou E, Papadopoulos I, Mazioti A, et al
    Asymptomatic bladder neurofibroma in neurofibromatosis type I.
    Minerva Pediatr (Torino). 2022;74:799-801.
    PubMed    


  220. HASHIMOTO M, Fujita K, Tomiyama E, Fujimoto S, et al
    Immunohistochemical Analysis of HER2, EGFR, and Nectin-4 Expression in Upper Urinary Tract Urothelial Carcinoma.
    Anticancer Res. 2023;43:167-174.
    PubMed    
    Abstract available

  221. TOMISAKI I, Harada M, Sakano S, Terado M, et al
    Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab.
    Anticancer Res. 2023;43:269-274.
    PubMed    
    Abstract available

  222. VON DEIMLING M, Rink M, Klemm J, Koelker M, et al
    Oncological validation and discriminative ability of pentafecta criteria after open radical cystectomy.
    BJU Int. 2023;131:90-100.
    PubMed    
    Abstract available

  223. QIU H, Makarov V, Bolzenius JK, Halstead A, et al
    KDM6A loss triggers an epigenetic switch that disrupts urothelial differentiation and drives cell proliferation in bladder cancer.
    Cancer Res. 2023 Jan 13:CAN-22-1444. doi: 10.1158/0008-5472.CAN-22-1444.
    PubMed    
    Abstract available

  224. CHOPRA S, Trepka K, Sakhamuri S, Carretero-Gonzalez A, et al
    Theranostic targeting of CUB domain containing protein 1 (CDCP1) in multiple subtypes of bladder cancer.
    Clin Cancer Res. 2023 Jan 17:CCR-22-1973. doi: 10.1158/1078-0432.CCR-22-1973.
    PubMed    
    Abstract available

  225. HORNAK J, Brisuda A, Babjuk M
    Transurethral resection of bladder cancer with or without fluorescence.
    Curr Opin Urol. 2023 Jan 12. doi: 10.1097/MOU.0000000000001071.
    PubMed    
    Abstract available

  226. ST-LAURENT MP, Suderman J, Black PC
    Re: A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Jan 3:S0302-2838(22)02866-4. doi: 10.1016/j.eururo.2022.
    PubMed    


  227. KLUMPER N, Holzel M, Eckstein M
    Reply to Jon Griffin. TIME for a Change? Multimarker Assessment of the Tumour Immune Microenvironment and Metastatic Site Biopsy to Improve Immunotherapy Response Prediction in Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.101
    Eur Urol. 2023 Jan 24:S0302-2838(23)00022-2. doi: 10.1016/j.eururo.2023.
    PubMed    


  228. QUAN C, Chen J, Hu J
    Re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107-14.
    Eur Urol. 2023 Jan 24:S0302-2838(23)00020-9. doi: 10.1016/j.eururo.2022.
    PubMed    


  229. VIDRA N, Beeren I, van Zutphen M, Aben KK, et al
    Longitudinal associations of adherence to lifestyle recommendations and health-related quality of life in patients with non-muscle invasive bladder cancer.
    Int J Cancer. 2023 Jan 3. doi: 10.1002/ijc.34418.
    PubMed    
    Abstract available

  230. NAKAMURA Y, Fukushima H, Yoshitomi K, Soma T, et al
    Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Dec 27. doi: 10.1111/iju.15136.
    PubMed    
    Abstract available

  231. NASELLI A, Pirola GM
    Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2023 Jan 18. doi: 10.1111/iju.15150.
    PubMed    


  232. PLIMACK ER, Zibelman MR
    Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert?
    J Clin Oncol. 2023;41:7-10.
    PubMed    
    Abstract available

  233. CRABB SJ, Hussain S, Soulis E, Hinsley S, et al
    A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:54-64.
    PubMed    
    Abstract available

  234. ROSENBERG JE, Park SH, Kozlov V, Dao TV, et al
    Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
    J Clin Oncol. 2023;41:43-53.
    PubMed    
    Abstract available

  235. STERNBERG CN, Petrylak DP, Bellmunt J, Nishiyama H, et al
    FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.
    J Clin Oncol. 2023;41:629-639.
    PubMed    
    Abstract available

  236. SADEGHI S, Quinn D, Dorff T, Pal S, et al
    EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:640-650.
    PubMed    
    Abstract available


  237. Erratum: DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    J Clin Oncol. 2023 Jan 25:JCO2202889. doi: 10.1200/JCO.22.02889.
    PubMed    


  238. LYON TD, Boorjian SA, Tyson MD
    In-Home Intravesical Therapy: The Future of Non-muscle Invasive Bladder Cancer Care Delivery?. Letter.
    J Urol. 2023 Jan 13:101097JU0000000000003176. doi: 10.1097/JU.0000000000003176.
    PubMed    


  239. PRUNTY M, Rhodes S, Rivero MJ, Callegari M, et al
    National Adherence to Guidelines for Antimicrobial Prophylaxis for Patients Undergoing Radical Cystectomy.
    J Urol. 2023;209:329-336.
    PubMed    
    Abstract available

  240. HUELSTER HL, Zemp L, Turner K, Gonzalez BD, et al
    Mobile Postoperative Symptom Intervention Tool and Biometric Monitoring After Radical Cystectomy: Pilot Study Evaluating Feasibility, Usability, and Potential Utility.
    J Urol. 2023;209:410-421.
    PubMed    
    Abstract available

  241. BRUN A, Koutlidis N, Thibault T, Escoffier A, et al
    [The impact of restaging transurethral resection on recurrence and progression free survival in patients with T1 high grade bladder cancer].
    Prog Urol. 2023 Jan 3:S1166-7087(22)00537-1. doi: 10.1016/j.purol.2022.
    PubMed    
    Abstract available

  242. FITOUSSI O, Roche JB, Riviere J, Wallerand H, et al
    Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy.
    Urol Int. 2023 Jan 19:1-7. doi: 10.1159/000528524.
    PubMed    
    Abstract available

  243. TACHIBANA T, Ikeda M, Shimura S, Amano N, et al
    Efficacy of Intravesical Instillation Therapy with Low-Dose Tokyo-172 Bacillus Calmette-Guerin to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer and Treat Carcinoma in situ: A Multi-Institutional Retrospective Study.
    Urol Int. 2023 Jan 16:1-9. doi: 10.1159/000527718.
    PubMed    
    Abstract available

  244. KORKES F, Timoteo F, Baccaglini W, Glina F, et al
    Postoperative Mortality Rate after Radical Cystectomy: A Systematic Review of Epidemiologic Series.
    Urol Int. 2023;107:96-104.
    PubMed    
    Abstract available

  245. ZANG Z, Kesavan NR, Esuvaranathan K
    UBC(R)Rapid Is Sensitive in Detecting High-Grade Bladder Urothelial Carcinoma and Carcinoma in situ in Asian Population.
    Urol Int. 2023;107:29-34.
    PubMed    
    Abstract available

  246. SCHNEIDEWIND L, Drager DL, Rossberg V, Nolting J, et al
    Prospective Evaluation of Health-Related Quality of Life in Patients with Metastatic Urothelial Carcinoma Undergoing Immunotherapy with Pembrolizumab: Symptom Burden Can Predict Survival.
    Urol Int. 2023;107:80-86.
    PubMed    
    Abstract available

  247. MICHAEL KGFT, Ravindranath N, Michael S, German A, et al
    Optimizing Upper-Tract Imaging for Non-Visible Haematuria.
    Urol Int. 2023;107:23-28.
    PubMed    
    Abstract available

  248. ZHANG Y, Ding H, Zhang Y, Tian J, et al
    Is Anti-Reflux Anastomosis an Advantage in an Orthotopic Ileal Neobladder? A Systematic Review and Meta-Analysis.
    Urol Int. 2023;107:1-14.
    PubMed    
    Abstract available

  249. EISMANN L, Bohn L, Buchner A, Casuscelli J, et al
    Age and ECOG Performance Status as Predictors of Survival of Patients with Upper Urinary Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy.
    Urol Int. 2023;107:72-79.
    PubMed    
    Abstract available

  250. SHARMA V, Chamie K, Schoenberg M, Lee VS, et al
    Natural history of multiple recurrences in intermediate-risk non-muscle invasive bladder cancer: lessons from a prospective cohort.
    Urology. 2022 Dec 24:S0090-4295(22)01071-8. doi: 10.1016/j.urology.2022.
    PubMed    
    Abstract available

  251. INOUE T
    Association of increased age with decreased response to intravesical instillation of Bacille Calmette-Guerin in patients with high-risk non-muscle invasive bladder cancer: Retrospective multi-institute results from the Japanese Urological Oncology Res
    Urology. 2022 Dec 28:S0090-4295(22)01085-8. doi: 10.1016/j.urology.2022.
    PubMed    


  252. TYSON MD, Mi L
    Preliminary Surgical Outcomes After Single Incision Robotic Cystectomy (SIRC).
    Urology. 2023;171:127-132.
    PubMed    
    Abstract available

  253. HOUENSTEIN HA, Jing Z, Elsayed AS, Ramahi YO, et al
    Analysis of Complications After Robot-Assisted Radical Cystectomy Between 2002-2021.
    Urology. 2023;171:133-139.
    PubMed    
    Abstract available

  254. AN L, Xiong L, Xu Q, Chen L, et al
    Incidental Diagnosis of Renal Pelvic Tumor in Patients Who Underwent Percutaneous Nephrolithotomy: A Report of 6 Cases and Review of the Literature.
    Urology. 2023;171:64-70.
    PubMed    
    Abstract available

  255. GOLZY M, Rosen G, Kruse RL, Hooshmand K, et al
    Holistic assessment of quality of life predicts survival in older patients with bladder cancer.
    Urology. 2023 Jan 17:S0090-4295(23)00045-6. doi: 10.1016/j.urology.2022.
    PubMed    
    Abstract available

  256. DIAS HF, Mochizuki Y, Kuhtreiber WM, Takahashi H, et al
    Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies.
    PLoS One. 2023;18:e0276423.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;